GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lupin Ltd (BOM:500257) » Definitions » Cyclically Adjusted Revenue per Share

Lupin (BOM:500257) Cyclically Adjusted Revenue per Share : ₹457.09 (As of Mar. 2025)


View and export this data going back to 1995. Start your Free Trial

What is Lupin Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Lupin's adjusted revenue per share for the three months ended in Mar. 2025 was ₹121.270. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹457.09 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Lupin's average Cyclically Adjusted Revenue Growth Rate was 3.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Lupin was 5.30% per year. The lowest was 4.60% per year. And the median was 5.10% per year.

As of today (2025-05-30), Lupin's current stock price is ₹1969.15. Lupin's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ₹457.09. Lupin's Cyclically Adjusted PS Ratio of today is 4.31.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Lupin was 5.18. The lowest was 1.48. And the median was 2.48.


Lupin Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Lupin's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lupin Cyclically Adjusted Revenue per Share Chart

Lupin Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 378.36 399.85 421.83 441.23 457.09

Lupin Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 441.23 448.95 455.52 457.55 457.09

Competitive Comparison of Lupin's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Lupin's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lupin's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lupin's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Lupin's Cyclically Adjusted PS Ratio falls into.


;
;

Lupin Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lupin's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=121.27/157.5517*157.5517
=121.270

Current CPI (Mar. 2025) = 157.5517.

Lupin Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 69.777 99.841 110.110
201509 73.534 101.753 113.858
201512 78.385 102.901 120.015
201603 92.717 102.518 142.489
201606 98.628 105.961 146.648
201609 94.727 105.961 140.848
201612 97.268 105.196 145.678
201703 93.857 105.196 140.569
201706 83.885 107.109 123.391
201709 85.485 109.021 123.538
201712 85.632 109.404 123.318
201803 89.219 109.786 128.036
201806 83.400 111.317 118.040
201809 85.724 115.142 117.298
201812 84.608 115.142 115.771
201903 83.847 118.202 111.760
201906 83.978 120.880 109.455
201909 84.479 123.175 108.056
201912 82.110 126.235 102.480
202003 81.983 124.705 103.577
202006 76.251 127.000 94.594
202009 83.156 130.118 100.688
202012 86.078 130.889 103.612
202103 82.586 131.771 98.744
202106 93.034 134.084 109.317
202109 88.196 135.847 102.287
202112 89.764 138.161 102.362
202203 84.179 138.822 95.536
202206 79.297 142.347 87.767
202209 89.877 144.661 97.886
202212 92.928 145.763 100.444
202303 94.645 146.865 101.532
202306 103.805 150.280 108.828
202309 108.131 151.492 112.456
202312 111.106 152.924 114.468
202403 106.955 153.035 110.112
202406 120.567 155.789 121.931
202409 120.174 157.882 119.922
202412 122.797 158.323 122.199
202503 121.270 157.552 121.270

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Lupin  (BOM:500257) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Lupin's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1969.15/457.09
=4.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Lupin was 5.18. The lowest was 1.48. And the median was 2.48.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Lupin Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Lupin's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Lupin Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lupin Ltd (BOM:500257) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
Off. Western Express Highway, 3rd floor, Kalpataru Inspire, Santacruz (East), Mumbai, MH, IND, 400055
Lupin Ltd is a specialty and generic drug manufacturing company. The company produces, develops, and markets branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) globally. It has a presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, GastroIntestinal, and other drug therapy segments. The operations of the company are limited to the segments, namely pharmaceuticals which derives key revenue, and others. It also maintains a pipeline in high-barrier markets such as Inhalation, Biosimilars, and Complex Injectables. The vast majority of the company's sales are generated in the United States, followed by India, and other countries.

Lupin Headlines

No Headlines